Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 13/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.53 |
| ▸ | HRH2 | P25021 | 2/20 | 0.53 |
| ▸ | HRH1 | P35367 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | HTR1B | P28222 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HTR1E | P28566 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19950156 | 0.95 | MEN1 (0.60) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL5237843 | 0.92 | KMT2A (0.54) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL5239282 | 0.88 | TMEM97 (0.52) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL22290980 | 0.88 | LMNA (0.57) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL5231132 | 0.88 | NPSR1 (0.50) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL5235772 | 0.87 | MEN1 (0.65) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL22291054 | 0.86 | CA1 (0.55) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL5232705 | 0.86 | MEN1 (0.53) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL9727540 | 0.86 | NPSR1 (0.68) | TMEM97SIGMAR1MEN1KMT2ANPSR1 | |
| SCHEMBL6132364 | 0.84 | GAA (0.69) | TMEM97SIGMAR1MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127906-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | UNIVERSITY OF SOUTH CAROLINA | 2025-04-24 | — | — | US | disclosed |
| CN-113677341-B | Bicyclic pyridine compositions and methods for their use in cancer treatment | 南卡罗莱纳大学 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023081452-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2023-05-11 | — | — | WO | disclosed |
| US-11572369-B2 | Bicyclic pyridine compositions and methods of using the same for cancer therapy | UNIVERSITY OF SOUTH CAROLINA (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220135583-A1 | BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY | UNIVERSITY OF SOUTH CAROLINA | 2022-05-05 | — | — | US | disclosed |
| EP-3917523-A1 | BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY | University of South Carolina (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113677341-A | Bicyclic pyridine compositions and methods of use for cancer treatment | 南卡罗莱纳大学 | 2021-11-19 | — | — | CN | disclosed |
| WO-2020160537-A1 | BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160537-A1 | BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127906-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | CDK8, CDK9, CDK18 | TMEM97 4735/4885SIGMAR1 4060/4885MEN1 2239/4885 |
| US-20220135583-A1 | BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY | DPYD, TK2, TYMP | TMEM97 4623/4885SIGMAR1 4525/4885MEN1 3123/4885 |
| US-11572369-B2 | Bicyclic pyridine compositions and methods of using the same for cancer therapy | DPYD, TK2, TYMP | TMEM97 4623/4885SIGMAR1 4525/4885MEN1 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.